Edoxaban: A direct oral anticoagulant.
Review published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2017)
Abstract
PURPOSE: The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and treatment of venous thromboembolism (VTE) are reviewed. SUMMARY: Although warfarin has been an established therapy for stroke prevention in AF and VTE, the need for agents with less monitoring requirements, fewer food and drug interactions, and a lower risk of major bleeding led to the development of direct oral anticoagulants (DOACs). Current DOACs work by either directly blocking thrombin (dabigatran) or inhibiting factor Xa (apixaban, edoxaban, and rivaroxaban). Edoxaban is the newest DOAC and only the second Food and Drug Administration-approved anticoagulant for once-daily administration. Unlike apixaban and rivaroxaban, edoxaban does not interact with the cytochrome P-450 system. The results of the ENGAGE AF-TIMI 48 and Hokusai-VTE trials demonstrated edoxaban's noninferiority to warfarin. However, the adverse-effect profile of edoxaban may limit the drug's use in clinical practice; in clinical trials, patients with AF who had a creatinine clearance of ≥95 mL/min had a higher rate of strokes with the use of edoxaban versus warfarin. CONCLUSION: A review of the literature showed that edoxaban, the most recently approved DOAC, is noninferior to warfarin for management of VTE (after parenteral anticoagulant therapy) and for stroke risk reduction in many patients with nonvalvular AF.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and treatment of venous thromboembolism (VTE) are reviewed. Although warfarin has been an established...
Por qué esto importa para la hirudoterapia
Esta revisión resume la farmacología, la farmacocinética y la eficacia clínica del edoxabán, un anticoagulante oral directo que actúa como inhibidor del factor Xa, para la prevención del accidente cerebrovascular en la fibrilación auricular y el tratamiento del tromboembolismo venoso. Detalla la no inferioridad del fármaco respecto a la warfarina, junto con advertencias específicas de seguridad sobre el aclaramiento renal. Este artículo resulta de interés indirecto para la ASH porque la inhibición del factor Xa es un mecanismo destacado presente en diversas secreciones de sanguijuela, como las que contienen antistasina. Comparar los inhibidores sintéticos del factor Xa con sus homólogos naturales derivados de sanguijuela contextualiza la potencia farmacológica de la saliva de la sanguijuela. Sin embargo, el estudio no tiene relevancia directa para la hirudoterapia; se centra estrictamente en un fármaco oral sintético, sin mención alguna a sanguijuelas, extractos de sanguijuela o datos biológicos comparativos.
Citación
Edoxaban: A direct oral anticoagulant.
Poulakos et al. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026